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Abstract
Background—Rapid point-of-care (POC) tests provide an economical alternative for rapid 
diagnosis and treatment of influenza, especially in public health emergency situations.
Objectives—To test the performance of a rapid influenza diagnostic test, QuickVue (Quidel) as a 
POC test against a real-time polymerase chain reaction (RT-PCR) assay for detection of influenza 
A and B in a developing country setting.
Study Design—In a prospective observational design, 600 patients with influenza-like illness 
(ILI) or with severe acute respiratory illness (SARI) who were referred to the Influenza Clinic of a 
tertiary care hospital in Srinagar, India from September 2012 to April 2013, were enrolled for 
diagnostic testing for influenza using QuickVue or RT-PCR. All influenza A-positive patients by 
RT-PCR were further subtyped using primers and probes for A/H1pdm09 and A/H3.
Results—Of the 600 patients, 186 tested positive for influenza A or B by RT-PCR (90 A/
H1N1pdm09, 7 A/H3 and 89 influenza B), whereas only 43 tested positive for influenza (influenza 
A = 22 and influenza B = 21) by QuickVue. Thus, the sensitivity of the QuickVue was only 23% 
(95% confidence interval, CI: 17.3-29.8) and specificity was 100% (95% CI: 99.1-100) with a 
positive predictive value (PPV) of 100% (95% CI 91.8-100) and a negative predictive value (NPV) 
of 74.3% (95% CI: 70.5-77.9) as compared to RT-PCR.
Conclusions—The high specificity of QuickVue suggest that this POC test can be a useful tool 
for patient management or triaging during a public health crisis but a low sensitivity suggests that 
a negative test result need to be further tested using RT-PCR.
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Influenza viruses cause outbreaks and epidemics that can spread rapidly, resulting in 
significant morbidity and mortality with an estimated 250,000 to 500,000 deaths annually.[1] 
In March 2009, an outbreak of novel H1N1 influenza A virus infection was detected in 
Mexico, with a rapid spread across many countries, resulting in pandemic.[2] This infection 
was associated with increased morbidity and mortality among children and younger adults 
compared with the usual seasonal influenza virus strains.[3,4] The emergence of the 
pandemic highlighted the challenges posed by rapid spread of viruses and fragility of health 
care infrastructure capacity.[5] Additionally, many countries could not handle the surge in 
virus testing because of the lack of laboratories with testing capacity, and the molecular tests 
being time-consuming and expensive. Hence simple bed-side point-of-care (POC) test 
systems are needed to handle testing capacity during public health emergency settings.
India witnessed its first case of pandemic A/H1N1pdm09 in May 2009 followed soon by a 
surge throughout the country, which overwhelmed the laboratory capacity for influenza 
testing. India has an extensive influenza surveillance network with many laboratories 
capable of testing for influenza.[6,7] While influenza circulation in most part of India reveals 
peaks during the monsoon periods in July–September, influenza circulation in the northern-
most states is observed during the peak winter months of December–March.[6,8] 
Immediately following the pandemic in 2009, we reported that pandemic and seasonal 
influenza viruses contribute significantly to respiratory illness in the northern Indian state of 
Jammu and Kashmir[8,9] where uptake of influenza vaccination is poor, even in high-risk 
populations.[10]
The gold standard reference methods for the diagnosis of influenza include, virus isolation 
in past years and molecular detection using real-time polymerase chain reaction assays (RT-
PCR) more recently. In comparison, commercially available rapid influenza diagnostic tests 
(RIDT) antigen detection ‘point of care’ immunoassay tests have the advantage of providing 
results much more quickly (within minutes).[11-13] These RIDT tests are simple to use and 
have the advantage of a fast turnaround, which can influence triage, diagnosis, initiation and 
duration of treatment and hospitalization. The rapid tests have a variable sensitivity ranging 
from 10-96%, even though the specificity consistently exceeds >90% for some tests.[12,13] 
While both molecular and POC assays have limitations for patient care, RIDTs might be 
useful tools during public health emergency response. During the initial phase of pandemic, 
a confirmatory test was required prior to initiation of antiviral. The QuickVue Influenza A 
and B test is a POC test for rapid diagnosis of influenza and differentiation of influenza A 
and B viruses.
We report our findings of the comparison of the QuickVue Influenza A and B test with that 
of the RT-PCR in the setting of a developing country where the volumes of patients are high 
and it would be greatly advantageous to have a RIDT available for quick initiation of 
therapy, specifically during pandemic periods. The study, to the best of our knowledge, is the 
first from this part of world.
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All patients with influenza-like illness (ILI) or with severe acute respiratory illness (SARI), 
who were referred to the Influenza Clinic at Sher-i-Kashmir Institute of Medical Sciences, 
Srinagar, Kashmir for testing for influenza between September 2012 and April 2013, were 
enrolled for the prospective observational study for comparative diagnostic testing for 
influenza using QuickVue or RT-PCR. We defined ILI as fever of 100°F (>37.2° C) 
accompanied by cough and/or sore throat, whereas SARI was defined as those patients with 
ILI who also require hospitalisation. The timing of study was selected based on the peak 
circulation of influenza in Srinagar.[8] The specimens were either collected in an area 
designated for collection or from hospital wards. Combined throat and nasal swabs were 
collected simultaneously in viral transport medium for RT-PCR testing for influenza 
viruses.[6,7] The lab personnel performing the RT-PCR assay were blinded to the results of 
the QuickVue test. QuickVue Influenza A and B (Quidel Corporation, San Diego, USA) is a 
lateral-flow immunoassay using highly sensitive monoclonal antibodies that are specific for 
antigens of both Influenza A and B virus, with no known cross reactivity to other normal 
flora or other respiratory pathogens.[14] The test involves the extraction of influenza A and B 
viral antigens. The patient specimen is placed in the ‘Extraction Reagent Tube’, during 
which time the virus particles get disrupted exposing internal viral nucleoproteins. After 
extraction the test strip is placed in the ‘Extraction Reagent Tube’ where nucleoproteins in 
the specimen react with the reagents in the test strip. If the extracted specimen contains 
influenza A or B antigens, a pink to red ‘Test Line’ along with a blue procedural ‘Control 
Line’ appears indicating a positive result. The Test Line for Influenza A or B develop at 
separate locations on the strip. In case of a negative sample, only the blue procedural Control 
Line will appear.[14] The QuickVue Influenza A and B test was carried out strictly according 
to the manufacturer’s instructions. RT-PCR was performed within 1-3 hours of sample 
collection. All specimens that were influenza A-positive by RT-PCR were further subtyped 
using primers and probes for A/H1pdm09 and A/H3.
Specimens positive for influenza A or B virus in the RT-PCR were regarded as true 
positives. The sensitivity, specificity, positive (PPV) and negative (NPV) predictive values of 
the QuickVue Influenza A and B test results compared with those of the RT-PCR assay were 
calculated using two-by-two contingency tables. Continuous variables were tested by 
student’s t-test, whereas categorical variables were tested for statistical significance using 
Fisher’s exact/chi-square test using Medcalc Version 12.7 software. Values have been 
expressed as mean + SD and a P < 0.05 was considered significant.
The study was approved by the Institute Ethics Committee of SKIMS and informed consent 
for participation was obtained for all patients.
Results
A total of 600 patients presenting with ILI (n = 469) or SARI (n = 131) were enrolled from 
September 2012 to April 2013 at the tertiary care hospital at SKIMS. Among enrolled 
patients, almost half were males (n = 330) and 353 patients were 18 years or older. The date 
of enrolment ranged from 1-6 days after onset of symptoms (median 4 days).
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Of the 600 recruited patients, 186 (31%) tested positive for influenza A or B by RT-PCR (97 
for influenza A and 89 for influenza B), whereas only 43 (7.17%) tested positive for 
influenza A (n = 22, 21 were H1N1pdm09, 1 was H3N2) and influenza B (n = 21) by 
QuickVue testing. All 43 specimens positive by QuickVue were also positive by RT-PCR, 
thus giving a sensitivity of only 23.1% (95% confidence interval, CI 17.3-29.8) and a 
specificity of 100% (95% CI 99.1–100), with a PPV of 100% (95%CI: 91.8-100) and a NPV 
of 74.3% (95% CI 70.5-77.9) [Table 1]. There was no difference in sensitivity of RIDT in 
patients with ILI (22.8; 95%CI: 16.5-30.1) or SARI (25% 95% CI: 10.7-44.9) (P = 0.67), 
whereas the specificity was 100% in both the groups [Table 1].
Any potential bias due to sampling or storage of kits was ruled out. All nasopharyngeal 
samples were collected for QuickVue and RT-PCR testing by well-trained staff members. 
The QuickVue kits were stored properly, not expired, and the tests were performed 
immediately as per the manufacturer’s instructions.
Analysis of QuickVue sensitivity by influenza types showed that there was no difference in 
the sensitivity for the influenza A and B and specificity was 100% for both influenza types 
[Table 2]. Further, both subtypes of influenza A/H1N1 pdm09 and A/H3 were detected by 
RITD assays (data not shown). We next assessed the performance of QuickVue among 
patients in different age groups. Of the 186 RT-PCR influenza positives, 51 were in those 
<18 years and 135 among those ≥18 years. While specificity and PPV was 100% for both 
age groups, the sensitivity was higher for children <18 years (37.3%, 95% CI 24.1-51.9), 
compared to those in ≥18 years (17.8%; 95% CI 11.7-25.3; P < 0.009) [Table 2].
When the percentage positivity of the QuickVue tests were correlated against the cycle 
threshold threshold (Ct), a Ct value of < 21 was associated with a near 100% positivity of 
the rapid test, whereas those with higher values of CT had progressively lower positivity 
rates [Figure 1]. Thus the RT-PCR Ct values were lower in those with QuickVue test results 
that were positive (mean ± SD 22.02 + 3.04, range 16-31, median 22) vs negative (mean ± 
SD 28.35 + 3.1, range 21-35, median 28; P < 0.0001). This suggests that specimens with a 
higher viral load (as shown by low Ct values in the RT-PCR assay) are more likely to be 
positive in the QuickVue assay.
The cost of a QuickVue was approximately USD $10 per test, compared to an approximate 
cost of USD 50 per test for RT-PCR. The results of QuickVue are available in 15 minutes, 
whereas that of the RT-PCR are usually available the next day (unless during public health 
emergency when results are available in about 4-6 hours).
Discussion
India faced a huge public health crisis during the recent 2009 pandemic, with tremendous 
pressure and resource constraint on the health care system. We undertook a prospective 
observational analysis to compare the performance of a POC test (QuickVue) with a gold-
standard RT-PCR assay to measure the utility of the POC test during public health 
emergencies. While we observed a very high specificity and PPV of the QuickVue Influenza 
A and B test for detection of influenza A or B, the sensitivity and NPV were very low, when 
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compared to RT-PCR in both age groups that we studied. Thus a positive QuickVue test 
provides a rapid confirmation of influenza positivity which can help facilitate patient 
management and quick initiation of antiviral therapy; however, a negative test will require 
further assessment using more standard tests for confirmation of influenza. While in India a 
confirmatory test was required prior to initiation of antiviral, Centers for Disease Control 
(CDC) recommends that decisions about starting antiviral treatment should not await 
laboratory confirmation of influenza.[15]
Our observation of low sensitivity (23%) with high specificity is in agreement with some 
other published studies.[12,13,16-23] Overall, while the specificity of various RITD tests is 
high, sensitivity varies from study to study. A recent review of 159 studies with 26 RITD 
assays revealed a pooled sensitivity 62.3%.[12] Some investigators have reported a higher 
sensitivity of RIDT when compared to viral culture. Cheng et al.,[24] reported an overall 
sensitivity of 68% and specificity of 96% compared with viral culture, whereas Tai et al.,[25] 
reported a overall sensitivity of 82% and specificity of 99%. Gordon reported an agreement 
of 86% between the two tests.[26] In a meta-analysis of rapid tests for influenza, QuickVue 
RIDT had the highest sensitivity (51%) of all RITDs;[13] note that the figure of 51% is much 
higher than the sensitivity in current study and may be due to characteristics of the study 
population. In the current study, no difference in sensitivity of detection of influenza A 
(including pandemic H1N1pdm09) and B were observed. This is in contrast to previous 
studies, where RITDs were shown to be more sensitive for influenza A than B.[18] Similar to 
recently reported studies, we were also able to detect pandemic A/H1N1pdm09.[27,28]
We identified few factors that might account for the low sensitivity of RITDs in current 
study. No deviations from the manufacturer’s recommended specimen type, sample storage, 
handling and processing were practiced and all specimens were tested immediately (within 3 
hours) of collection. However, a possible mechanism for the low sensitivity could be the use 
of twin swabs in RT-PCR, which could lead to a higher viral load, and only a single 
nasopharyngeal swab in the RIDT test. The choice of a reference standard has also been 
reported to affect the sensitivity of the RIDT tests. For example, sensitivities have generally 
been higher when RIDT influenza tests were compared with viral culture, than when they 
were compared with RT-PCR.[12,13] In the current study, we only used RT-PCR which could 
account for the lower measured sensitivity of detection by RIDT. The median duration of 
symptoms in our patients at the time of collection of swabs was 4 days (range 1–6 days). 
Performance of the rapid test has been reported to vary by the day of presentation, with a 
sensitivity of 41.7% for samples from children presenting on the day of symptom onset and 
a sensitivity of 72.1% for samples from children presenting one or more days post-symptom 
onset.[26] Thus a second swab collected after the day of the onset of the symptoms may help 
increase the sensitivity of the assay.
Our results emphasize that clinicians should understand that negative results of influenza 
testing do not exclude influenza virus infection, as a variety of factors can influence test 
results. Some of these factors include the time from the onset of illness to the collection of 
the specimen, prevalence of the circulating influenza viruses in the studied population, 
improper sample collection, use of clinical specimen or swab other than those 
recommended, prolonged time between the onset of illness and sample collection, improper 
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storage or handling and testing of upper respiratory specimens in a patient with predominant 
lower respiratory disease.[5]
The current study was conducted in a period of high influenza activity. The rate of false-
negative (and true-positive) results are more likely to occur when disease prevalence is high 
in the community.[6] Likewise, the PPV is the highest if the activity of influenza is high. The 
high PPV of the QuickVue assay observed in this study indicates that positive results do not 
need to be confirmed by RT-PCR and can be reported to the treating physician immediately 
in times of both low and high influenza rates. However, negative QuickVue Influenza A + B 
results, as well as negative results of other RIDT antigen assays, should be confirmed by RT-
PCR. This is even more important during the influenza season, because of decreasing NPV 
with increasing influenza virus incidence.
We observed a higher sensitivity of RITD for influenza detection among children as 
compared to adults, even as the specificity in both age groups was similar. These 
observations are in agreement with previous studies where sensitivity was reported to be 
lower in adults when compared with children, even when adjusted for brand of RIDT, 
specimen type or reference standard.[18] Higher viral loads and prolonged shedding in 
children than in adults could contribute to the higher sensitivity seen in children.[6]
Lower Ct values on RT-PCR in our patients was associated with a significantly higher 
positivity of RIDT tests, suggesting that a higher viral load was associated with a higher 
positivity of the RIDT antigen test; this finding is similar to a recently published report.[28] 
The twin swabs used in the RT-PCR samples might also have yielded a higher positivity 
because of a higher viral load due to a greater volume of the specimen collected by two 
swabs as compared to one swab in the RIDT test. Recent reports suggest that there is an 
inverse relationship between Ct values and viral load and those therefore qualitative results 
from RT-PCR assays can be converted into quantitative viral load values in clinical samples 
without running standard curves in parallel.[29]
Based on this information, we propose an alternate algorithm for influenza testing during a 
public health emergency: RIDTs can be used as a first screening assay for patient 
management, expected to identify almost one-fourth of influenza-positive cases. The 
remaining RITD negative cases should be tested by RT-PCR for influenza confirmation. In 
addition, as RIDT-positive cases likely were detected among those with high viral loads, 
positive RIDT likely represent cases severe disease,[30] which can then receive immediate 
care and intervention. The use of RITD as first line of testing can further be assessed based 
on the cost; the RITD cost is US$10 and the RT-PCR cost five times as high. The lower cost 
along with a fast turnaround time argues for the use of RIDTs as the first screening 
procedure, particularly during times of high influenza activity.
Our results also reinforce CDC guidelines,[15] that decisions about starting antiviral 
treatment should not wait for laboratory confirmation of influenza. Instead, antiviral agents 
should be started as early as possible in patients with confirmed or suspected influenza who 
are hospitalised; have severe, complicated, or progressive illness; or are at higher risk for 
influenza complications.[15] Antiviral agents can also be considered for other patients if 
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treatment can be started within 48-hours of illness onset. However, clinical practice may 
vary among countries, and some studies show that physicians base antiviral therapy 
decisions on the results of influenza testing. In India, government response included 
initiation of antiviral therapy only after positive influenza test results. Since RIDT tests are 
used as rapid tests for decisions about patient management, the test provides a tool for quick 
confirmation of influenza during public health emergency situations. Additionally, a positive 
RITD test would quickly indicate presence of influenza in population, which can help policy 
makers develop appropriate intervention strategies. The development of more sensitive POC 
rapid diagnostic tests with higher sensitivity is urgently needed.
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Relationship between Ct values by RT-PCR and influenza positivity by Quickvue. The Ct 
values obtained for RT-PCR for influenza specific PCR (X-axis) are plotted against percent 
positivity by Quickvue test (Y-axis). Lower Ct values (proxy for high viral loads) correlated 
with higher positivity by Quickvue assay.
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Table 1
Performance of QuickVue versus RT-PCR for detection of influenza virus among patients 
with influenza-like illness or severe acute respiratory illness at Sher-i-Kashmir Institute of 
Medical Sciences, Srinagar, India
Overall SARI ILI
Number tested 600 131 469
RT-PCR positive N (%) 186 (31) 28 (21.4) 158 (33.7)
QuickVue positive N (%) 43 (7.2) 7 (5.3) 36 (7.7)
Sensitivity (%) (95% CI) 23.1 (17.3-29.9) 25 (10.7-44.9) 22.8 (16.5-30.1)
Specificity (%) (95% CI) 100 (99.1-100) 100 (96.5-100) 100 (98.8-100)
PPV (%) (95% CI) 100 (91.8-100) 100 (59.0-100) 100 (90.3-100)
NPV (%) (95% CI) 74.3 (70.5-77.9) 83.1 (75.3-89.2) 71.8 (67.3-76)
RT-PCR: Real-time polymerase chain reaction, CI: Confidence interval, PPV: Positive predictive value, NPV: Negative predictive value, ILI: 
Influenza-like illness, SARI: Severe acute respiratory illness
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Table 2
Sensitivity, specificity, positive and negative predictive values of QuickVue assay, by 
influenza types and age group, Sher-i-Kashmir Institute of Medical Sciences Srinagar, 
India
Influenza A Influenza B Children (≤18 years) Adults (≥18 years)
Number tested 97 89 247 353
RT-PCR positive N (%) 97 (100) 89 (100) 51 (20.6) 135 (38.2)
QuickVue positive N (%) 22 (22.7) 21 (23.6) 19 (7.7) 24 (6.8)
Sensitivity (%) (95% CI) 22.7 (14.8-32.3) 23.6 (15.2-33.8) 37.3 (24.1-51.9)* 17.8 (11.7-25.3)*
Specificity (%) (95% CI) 100 (99.1-100) 100 (99.1-100) 100 (98.1-100) 100 (98.3-100)
PPV (%) (95% CI) 100 (84.6-100) 100 (83.9-100) 100 (82.4-100) 100 (85.8-100)
NPV (%) (95% CI) 84.7 (81.2-87.8) 85.9 (82.5-88.9) 86 (80.8-90.2) 66.3 (60.9-71.4)
*
Sensitivity of QuickVue higher for children≤18 years vs adults. RT-PCR: Real-time polymerase chain reaction, PPV: Positive predictive value, 
NPV: Negative predictive value, CI: Confidence interval
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